Cancer Care of Western North Carolina

Colon Cancer News

Personalized Precision Medicine Treatment of Colon Cancer: What Every Patient Should Know (July 17, 2017)

The purpose of precision cancer medicine is not to categorize or classify cancers solely by site of origin, but to define the genomic alterations in the cancer’s DNA that are driving that specific cancer.  Precision cancer medicine utilizes molecular... Continue Reading

SUNSHINE: Vitamin D Slows Colon Cancer Progression (July 6, 2017)

The first-ever completed comparative clinical trial of the use of vitamin D as a colorectal cancer therapy has shown that disease progression is slowed with high-dose supplements according to lead author Kimmie Ng, MD, of the Dana Farber Cancer Institute... Continue Reading

Shorter Duration Chemotherapy Possible for Early Stage Colon Cancer (June 26, 2017)

Many colon cancer patients can cut their chemotherapy regimen in half, improving their quality of life and reducing their chances of having debilitating side effects, according to the results of a major study released at the American Society of Clinical... Continue Reading

Know Your Treatment Options: Colorectal Cancer Liver Metastases (March 13, 2017)

Nearly 136,000 Americans are expected to be diagnosed with colorectal (CRC) cancer this year,1 and more than 50% will have their cancer spread to their liver.2  Many individuals with CRC involving the liver erroneously conclude that they have no treatment... Continue Reading

Inflammatory Bowel Disease: More Common than Previously Thought (November 8, 2016)

A recent report reveals that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), effect an estimated 3.1 million (1.3%) U.S. adults.  This is an increase from a report released in 1999 estimating that 1.8... Continue Reading

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (July 28, 2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These... Continue Reading

Stent Placement Reduces Need for Stoma in Some Colorectal Cancers (June 27, 2016)

The placement of a stent as initial emergency treatment for colon obstruction reduces the need for a stoma without adversely affecting outcomes for patients with potentially curable colorectal cancer. These results were recently presented at the 2016... Continue Reading

New Treatment May Reduce Precancerous Polyps in Both Large and Small Intestine in Hereditary Cancer Patients (May 26, 2016)

A new study published in the Journal of the American Medical Association (JAMA), has reported a new prevention treatment for individuals at high risk of developing colon cancer due to the APC (adenomatous polyposis coli) gene. Inheriting a mutation in... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer (May 11, 2016)

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently... Continue Reading

Latest Colon Cancer News By Stage


Adjuvant (I-III, A-C) Colon Cancer

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (July 28, 2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These... Continue Reading

Stent Placement Reduces Need for Stoma in Some Colorectal Cancers (June 27, 2016)

The placement of a stent as initial emergency treatment for colon obstruction reduces the need for a stoma without adversely affecting outcomes for patients with potentially curable colorectal cancer. These results were recently presented at the 2016... Continue Reading

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

Advances in Genomic Testing-What you Need to Know (September 29, 2014)

Q: What is genomic testing? A: Genomic testing looks at a group of genes and their varying levels of expression. This gene expression or activity can characterize how genes interact with one another and predict the behavior of certain tissues within... Continue Reading

Oncotype DX Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being (September 22, 2014)

REDWOOD CITY, Calif., Sept. 12, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer... Continue Reading

More Adjuvant (I-III, A-C) Colon Cancer

Screening/Prevention Colon Cancer

Inflammatory Bowel Disease: More Common than Previously Thought (November 8, 2016)

A recent report reveals that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), effect an estimated 3.1 million (1.3%) U.S. adults.  This is an increase from a report released in 1999 estimating that 1.8... Continue Reading

New Treatment May Reduce Precancerous Polyps in Both Large and Small Intestine in Hereditary Cancer Patients (May 26, 2016)

A new study published in the Journal of the American Medical Association (JAMA), has reported a new prevention treatment for individuals at high risk of developing colon cancer due to the APC (adenomatous polyposis coli) gene. Inheriting a mutation in... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection (May 2, 2016)

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing... Continue Reading

Anesthesia Increases Colonoscopy Risks (March 4, 2016)

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of exam that a doctor uses to check the lining of the... Continue Reading

More Screening/Prevention Colon Cancer

Stage IV (D)/Relapsed Colon Cancer

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

Lonsurf® Approved for the Treatment of Colorectal Cancer (September 30, 2015)

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although... Continue Reading

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing (August 24, 2015)

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (August 11, 2015)

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers... Continue Reading

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment (June 23, 2015)

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University... Continue Reading

More Stage IV (D)/Relapsed Colon Cancer